AOI Biosciences株式会社
Ibaraki, JP · 6 known investors
AOI Biosciences is a Japanese biotech company focused on infectious diseases and autoimmune disorders, combining data analysis technology with proprietary bio-technology. It operates diagnostic testing, drug discovery, and drug discovery support businesses.
Also known as AOI Biosciences Inc. · Revorf · アオイバイオ · 株式会社Revorf
Founders & leadership
Investors · 6
Also in the syndicate · 1
Company profile
researched Aug 2026AOI Biosciences株式会社 (AOI Biosciences Inc., also referred to as アオイバイオ, formerly named Revorf) is an Osaka-based biotechnology company established in November 2019. It focuses on infectious disease and autoimmune disease, combining information-analysis technology with proprietary biotechnology across three business lines: clinical testing, drug discovery, and drug discovery support.
One pillar is built on the "neo-self" theory proposed by Professor Hisashi Arase of Osaka University, a collaboration partner, which holds that self proteins can be recognized as foreign when bound to another molecule and thereby trigger autoimmune disease. Using this platform, the company operates the β2GPI neo-self antibody blood test for infertility and recurrent pregnancy loss, and provides diagnostic-development and drug-discovery support. It has an exclusive license from Osaka University to perform the test and describes itself as the sole testing institution receiving these measurements; the test is certified as advanced medical care (先進医療) in Japan. The company is also developing a next-generation antibody-drug conjugate (ADC) platform that targets neo-self antigens with high specificity for affected organs, aiming to reduce the side effects of existing symptomatic autoimmune therapies.
The second pillar applies high-performance computational processing of biological information to biomarker development and pharmaceutical partners' drug discovery, including allosteric drug discovery using Toshiba's quantum-inspired optimization solution SQBM+ to improve prediction of allosteric regulation sites in proteins. The company also applies RNA and other genome detection/analysis technologies for biomarker development at genetic-diagnostics companies and drug discovery support for pharmaceutical firms, and pursues data analysis and AI development in infectious disease and healthcare with external companies and academia.
Founding story
The representative director, Shinichi Sueda, is a physician who practiced as a nephrologist for six years after graduating from university. He describes feeling powerless when unable to help patients with autoimmune diseases and infections that suddenly take away ordinary health, and founded the company around the goal of protecting that "ordinary health" by fusing information analysis technology with proprietary biotechnology.
Business model
Revenue-generating clinical testing (contract measurement of the β2GPI neo-self antibody test as an advanced medical care service, run from its own registered testing center) is combined with drug discovery support and diagnostics-development support services for pharmaceutical and genetic-diagnostics companies. For its own therapeutic pipeline, the stated plan is to first pursue joint research and development with pharmaceutical companies, then secure its own patents on new drugs and license them out to pharmaceutical companies.
Fees from performing the β2GPI neo-self antibody test as the exclusive testing institution, contracted biomarker development and drug discovery support work for pharmaceutical and diagnostics companies, and planned out-licensing of internally patented drug candidates; grant funding has also been received from public and bank programs.
Traction
The β2GPI neo-self antibody test is certified as advanced medical care in Japan and is performed by the company as the exclusive licensee from Osaka University. Cited clinical research indicates that among patients testing positive who received corresponding treatment, live birth rates in recurrent pregnancy loss were about 1.7 times or more higher and pregnancy rates in infertility more than double. Overseas rollout has started in Indonesia and Malaysia with Sumitomo Corporation. A proof of concept for the neo-self antigen antibody ADC is planned within 2026, with full commercialization and new drug development targeted from 2027. Investors listed include Bio Engineering Capital, UntroD Capital Japan, ZACROS, Sumitomo Corporation, Nippon Venture Capital and individual investor Mamoru Taniya, at a Series B stage.
Latest developments
In February 2026 the company obtained ISO/IEC 27001 information security management certification. On 2 March 2026 its project "development of a groundbreaking autoimmune disease therapeutic platform using anti-neo-self antigen antibodies" was selected for an excellence prize in the manufacturing category of Senshu Ikeda Bank's 22nd Innovation R&D grant, with a plan to obtain ADC proof of concept within 2026 and move to commercialization from 2027. On 23 March 2026 it won the startup category prize at the NIKKEI THE PITCH GROWTH 2025-2026 final, cited for its neo-self-based diagnostic technology and allosteric site prediction technology.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positioned as the exclusive licensee and sole testing institution for the Osaka University-derived β2GPI neo-self antibody test in Japan, where the test has been certified as advanced medical care; recognized in Japanese startup programs, winning the startup category prize at the NIKKEI THE PITCH GROWTH 2025-2026 final and an excellence prize in Senshu Ikeda Bank's 22nd Innovation R&D grant program.
The company's approach rests on the neo-self mechanism as an explanation of the root cause of autoimmune disease, giving it both a novel blood-based test for infertility and recurrent pregnancy loss (exclusively licensed from Osaka University and certified as advanced medical care) and a route to organ-specific ADC therapeutics intended to replace symptomatic steroid and biologic treatment. On the computational side it combines allosteric site prediction with quantum-inspired optimization (Toshiba's SQBM+) to address proteins considered difficult to drug.
Technology
Core technologies are (1) the neo-self theory platform for detecting and targeting neo-self antigens and antibodies, underpinning the β2GPI neo-self antibody blood test and a next-generation neo-self-antigen-directed antibody-drug conjugate concept, and (2) biological-information computation, including allosteric site prediction using Toshiba Digital Solutions' quantum-inspired optimization solver SQBM+, plus RNA and genome detection/analysis and AI-based data analysis.
Go-to-market
Domestically the test is delivered through medical institutions under Japan's advanced medical care framework (certification obtained via The University of Tokyo Hospital) from the company's own registered testing center. International expansion of the β2GPI neo-self antibody test is carried out with Sumitomo Corporation, including launches in Indonesia (with a joint research agreement with the Hermina Group) and Malaysia. Drug discovery work is pursued through corporate and academic partnerships, such as with Toshiba Digital Solutions and Osaka University, and government/bank grant programs.
Fertility and obstetrics/gynecology clinicians and their infertility and recurrent-pregnancy-loss patients (via the β2GPI neo-self antibody test), pharmaceutical companies seeking drug discovery targets and allosteric drug discovery, and genetic-diagnostics companies needing biomarker development.
Geography
Headquarters, testing center at the Saito Bio Innovation Center in Ibaraki, Osaka Prefecture (Osaka Prefecture clinical laboratory registration No. 179), plus a Suita office located inside the Research Institute for Microbial Diseases at Osaka University. Overseas business development of the β2GPI neo-self antibody test has begun in Indonesia and Malaysia.
History
Established in November 2019. Under the earlier name Revorf, the company raised about JPY 300 million in March 2021, announced a strategic partnership and capital participation with Toshiba Digital Solutions in August 2024 around SQBM+-based expansion of druggable protein targets, entered capital and business alliances with Sumitomo Corporation (October 2024, for overseas expansion of infertility/recurrent-pregnancy-loss testing) and ZACROS (October 2024), and raised roughly JPY 300 million in total in October 2024. In 2022 it signed a contract with Teijin Pharma on single-cell gene expression analysis for drug target discovery. In 2025 the β2GPI neo-self antibody test was certified as advanced medical care by Japan's Ministry of Health, Labour and Welfare, the company was selected for the Go-Tech growth-oriented SME R&D support program, and it started business development in Indonesia and Malaysia. In February 2026 it obtained ISO/IEC 27001 (ISMS) certification, in March 2026 its anti-neo-self antigen antibody autoimmune therapeutic platform received an excellence prize under Senshu Ikeda Bank's Innovation R&D grant, and it won the startup category prize at the NIKKEI THE PITCH GROWTH 2025-2026 final.
Risks & controversies
The therapeutic program is early: proof of concept for the neo-self antigen ADC is only targeted for 2026 with commercialization from 2027, and the plan depends on joint development with, and eventual out-licensing to, pharmaceutical companies. The β2GPI neo-self antibody test is provided under Japan's advanced medical care framework rather than standard insurance coverage, and the testing business relies on an exclusive license from Osaka University; overseas expansion depends on partners such as Sumitomo Corporation and local hospital groups.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 12
launches, deals, and filingsThe company received the startup category prize at the final of NIKKEI THE PITCH GROWTH 2025-2026, cited for the novelty and social implementation of its neo-self-based diagnostic technology and allosteric site prediction technology.
Its project on a groundbreaking autoimmune disease therapeutic platform using anti-neo-self antigen antibodies (next-generation ADC) was selected for an excellence prize in the manufacturing category of the 22nd Innovation R&D grant run by Senshu Ikeda Bank.
The company announced it obtained certification under the international information security management system standard ISO/IEC 27001.
Research led by Hideto Yamada of Teine Keijinkai Hospital's recurrent pregnancy loss center (Osaka University visiting professor and AOI Biosciences scientific advisor) with Yosuke Ono and Osamu Yoshino of University of Yamanashi reported that anticoagulant treatment improves pregnancy outcomes in neo-self antibody positive women with infertility.
The company began business development of its new infertility and recurrent pregnancy loss test, the β2GPI neo-self antibody test, in Malaysia, together with Sumitomo Corporation.
Selected under the FY2025 Growth-Type SME R&D Support Project (Go-Tech) for a project to establish the β2GPI neo-self antibody test method via development of stable high-expression cells for neo-self antigens, including cell improvement, mass culture methods and kit development.
The company started business development of the β2GPI neo-self antibody test in Indonesia together with Sumitomo Corporation, signing a joint research agreement with the Hermina Group.
The β2GPI neo-self antibody test provided by the company received advanced medical care (先進医療) certification from Japan's Ministry of Health, Labour and Welfare via The University of Tokyo Hospital.
Under the name Revorf, the company formed a capital and business alliance with ZACROS to create synergies from both companies' strengths and contribute to advances in medical technology.
Under the name Revorf, the company formed a capital and business alliance with Sumitomo Corporation to address declining birthrate issues through global expansion of infertility and recurrent pregnancy loss testing.
Under the name Revorf, the company entered a strategic partnership with Toshiba Digital Solutions, which also took a capital stake, to use the quantum-inspired optimization solution SQBM+ to expand the range of proteins that can be targeted for drug discovery.
Under the name Revorf, the company concluded a contract with Teijin Pharma covering drug discovery target gene exploration using single-cell gene expression analysis of human samples.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- AOI Biosciences株式会社aoibio.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does AOI Biosciences株式会社 do?
- Japanese biotech running a neo-self antibody testing business plus drug discovery and drug discovery support in autoimmune disease and infection.
- Who are AOI Biosciences株式会社's investors?
- AOI Biosciences株式会社's investors include i-nest capital, Nippon Venture Capital, NOW Japan, Seiho Investment Works, UntroD Capital.
- Where is AOI Biosciences株式会社 headquartered?
- AOI Biosciences株式会社 is headquartered in Ibaraki, JP.